Epidemiology of Immune-mediated Inflammatory Diseases: Incidence, Prevalence, Natural History, and Comorbidities

Overview

Journal J Rheumatol Suppl

Specialty Rheumatology

Date 2010 May 4

PMID 20436161

Citations 121

Authors

Hani El-Gabalawy

Lyn C Guenther

Charles N Bernstein

Affiliations

Soon will be listed here.

Abstract

Immune-mediated inflammatory diseases (IMID) present a group of common and highly disabling chronic conditions that share inflammatory pathways. Several incidence and prevalence studies of IMID during the past decades have reported a considerable variation of the disease occurrence among different populations. Overall, the estimated prevalence of IMID in Western society is 5%-7%. This article provides an overview of studies of the incidence, prevalence, natural history, and comorbidities of IMID.

Citing Articles

Specific Composition Diets and Improvement of Symptoms of Immune-Mediated Inflammatory Diseases in Adulthood-Could the Comparison Between Diets Be Improved?.

Guerrero Aznar M, Villanueva Guerrero M, Beltran Garcia M, Hernandez Cruz B Nutrients. 2025; 17(3).

PMID: 39940351 PMC: 11819864. DOI: 10.3390/nu17030493.

Editorial: Biologic drugs in immune-mediated inflammatory diseases, validation, drug-utilization, effectiveness, regulation, costs, and safety in the real-world.

Convertino I, Lopes L, Pratt N, Ingrasciotta Y, Tuccori M Front Pharmacol. 2025; 15:1542453.

PMID: 39867659 PMC: 11758181. DOI: 10.3389/fphar.2024.1542453.

Global trends in immune mediated inflammatory diseases: Psoriasis, atopic dermatitis, multiple sclerosis, inflammatory bowel disease, and rheumatoid arthritis.

Gelabert-Mora A, Chiang B, Lee A, Sinha M, Abuabara K JAAD Int. 2025; 18():177-179.

PMID: 39834709 PMC: 11742845. DOI: 10.1016/j.jdin.2024.11.003.

The Long-Term Impact of Polysaccharide-Coated Iron Oxide Nanoparticles on Inflammatory-Stressed Mice.

Goring J, Schwarz C, Unger E, Quaas R, Hilger I J Xenobiot. 2024; 14(4):1711-1728.

PMID: 39584956 PMC: 11587046. DOI: 10.3390/jox14040091.

Psoriasis and inflammatory bowel disease: concomitant IMID or paradoxical therapeutic effect? A scoping review on anti-IL-12/23 and anti-IL-23 antibodies.

Bezzio C, Cavalli C, Franchellucci G, Dal Buono A, Gabbiadini R, Scalvini D Therap Adv Gastroenterol. 2024; 17:17562848241299564.

PMID: 39575159 PMC: 11580083. DOI: 10.1177/17562848241299564.